Astellas, Eisai To Double China Sales Forces To Meet Growing Demand
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and Eisai each has plans to double its sales force in China in an effort to meet a rising demand for drugs as the government expands insurance coverage